Clinical Trial Update: Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) [Phase 3]

View source ↗

Summary

Open-label Phase 3 study evaluating KRN23 for osteomalacia in adults with X-linked hypophosphatemia completed; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomalacia
• X-linked Hypophosphatemia

Drugs mentioned

• KRN23 (burosumab)

Snippet

Sponsor: Kyowa Kirin, Inc. | Conditions: X-linked Hypophosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2018-09-25